You just read:

Epygenix Therapeutics Receives Orphan Drug Designation From the U.S. FDA for EPX-100 and EPX-200 in the Treatment of Patients With Dravet Syndrome

News provided by

Epygenix Therapeutrics, Inc.

Apr 25, 2017, 08:00 ET